Source: Hamilton Devices.
  • Lifeist’s (LFST) CannMart subsidiary has signed a distribution agreement with Hamilton Devices
  • Hamilton is one of the leading U.S. manufacturers and suppliers of vape hardware
  • CannMart is the first distributor of Hamilton products across Canada
  • Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness
  • Lifeist Wellness Inc. (LFST) is holding steady at $0.095 per share

Lifeist’s (LFST) CannMart subsidiary has signed a distribution agreement with Hamilton Devices.

Hamilton is one of the leading U.S. manufacturers and suppliers of vape hardware. It delivers extract-based cannabis products such as distillate, live resin and shatter through industry-wide 510 thread carts. 

CannMart is the first distributor of Hamilton products across Canada. The agreement runs until October 2024 with an initial six months of exclusivity.

CannMart intends to leverage its master distributor status to sell Hamilton products directly into its expanding retail store network of over 2,500 stores across Canada.

Daniel Stern, CEO of CannMart, commented on the news:

“It’s a privilege to be selected by Hamilton Devices as its exclusive B2B distribution partner for Canada. We can’t wait to leverage our established relationships to bring their innovative vaporizer technologies to Canadian consumers.”

CannMart is a Canadian licensed cannabis producer. It operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial governments.

Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness.

Lifeist Wellness Inc. (LFST) is holding steady at $0.095 per share as of 1:50 pm ET.


More From The Market Online
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.

The Market Online’s Weekly Cannabis Report – Feb. 23, 2024

Canopy Growth (TSX:WEED) is rolling out five new pre-roll products across its 7ACRES and Hiway brands.
WELL Health - Hamed Shahbazi, Founder and CEO (third from right).

WELL Health streamlining business towards profitable growth

WELL Health (TSX:WELL) has made an integration update to streamline its business operations and position itself for profitable growth.